Sponsor

Navire Pharma Inc., a BridgeBio company

Clinical research sponsor

Published trials2

Recruiting shown0

Roles1

SourceClinicalTrials.gov

Clinical trials

2 shown

SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS MutationNCT05375084 · lead sponsor · 2022-10-20

TERMINATED

SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C MutationNCT05480865 · lead sponsor · 2022-07-06

TERMINATED

Sponsor roles

lead sponsor2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.